Menopause Review
facebook
eISSN: 2299-0038
ISSN: 1643-8876
Menopause Review/Przegląd Menopauzalny
Current issue Archive Online First About the journal Editorial board Abstracting and indexing Subscription Contact Ethical standards and procedures Special Issues Instructions for authors Publication charge
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank


Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
3/2024
vol. 23
 
Share:
Send email
Share:
abstract:
Original paper

Serum fibronectin levels in malignant and benign endometrial diseases

Dimitar Mitev
1
,
Sergei Slavov
1
,
Georgi Dimitrov
1
,
Irena Shikova
1
,
Julieta Hristova
2
,
Stoyan Kostov
3, 4
,
Angel Yordanov
5

  1. University Hospital of Obstetrics and Gynecology “Maichin dom” – Sofia, Medical University – Sofia, Bulgaria
  2. Department of Clinical Laboratory and Clinical Pharmacology – University Hospital “Alexandrovska”, Medical University – Sofia, Bulgaria
  3. Department of Gynecology, Hospital “Saint Anna”, Medical University – “Prof. Dr. Paraskev Stoyanov”, Varna, Bulgaria
  4. Research Institute, Medical University Pleven, Pleven, Bulgaria
  5. Department of Gynecologic Oncology, Medical University Pleven, Pleven, Bulgaria
Menopause Rev 2024; 23(3): 140-144
DOI: https://doi.org/10.5114/pm.2024.143419
Online publish date: 2024/10/14
View full text Get citation
 
PlumX metrics:
Introduction
Endometrial cancer is currently the most common malignancy of the female reproductive system. The significance of the disease is determined by the search for additional biomarkers with the aim to optimize earlier diagnosis and to help for timely treatment. The objective of this study was to assess the serum levels of fibronectin (FN) in patients with malignant endometrial pathology and to compare them with patients with benign pathology and healthy women.

Material and methods
We analyzed serum FN levels in women with malignant and benign pathology of the endometrium. Blood serum samples were collected from 100 patients – 50 diagnosed with endometrial cancer and 50 with confirmed endometrial polyps. In addition, 50 control subjects were tested. Fibronectin levels were measured by enzyme-linked immunosorbent assay (ELISA) according to the protocol

Results
Statistical analysis was performed and the results demonstrated statistical significances (p = 0.008) of FN levels in the group with endometrial cancer (mean 482.73, median 409.12 µg/ml) compared to the control group (mean 346.86, median 258.87 µg/ml), but no significant difference in FN levels was observed between the group with endometrial malignancy and the group with benign pathology of the endometrium. In addition, in the cancer group FN levels did not show any significant differences depending on the histologic type.

Conclusions
The serum FN concentration can be used as an additional tumor marker for gynecological malignancies and can be a potential diagnostic and prognostic marker for malignant endometrial pathology as well as for other gynecological malignancies.

keywords:

endometrial cancer, fibronectin, polyps, benign pathology of the endometrium, malignant pathology of the endometrium

Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2026 Termedia Sp. z o.o.
Developed by Termedia.